The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
Open accessAbstract
Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Self-citationA prospective randomized trial
(1995) · Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) · doi:10.4030/jjcs1979.20.2_191 · Cited by 1,619
Flowers, M. E. D., Inamoto, Y., Carpenter, P. A., Lee, S. J., Kiem, H.-P., Petersdorf, E. W., Pereira, S. E., Nash, R. A., Mielcarek, M., Fero, M. L., et al. (2011) · Blood · doi:10.1182/blood-2010-08-302109 · Cited by 690
Self-citationRowlings, P. A., Przepiorka, D., Klein, J. P., Gale, R. P., Passweg, J. R., Jean Henslee‐Downey, P., Cahn, J., Calderwood, S., Gratwohl, A., Socié, G., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.1112925.x · Cited by 685
Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I., Lu, J.-G., Gajewski, J., Durett, A., Cleary, K., et al. (2000) · Blood · doi:10.1182/blood.v95.1.83 · Cited by 263
Tumor necrosis factor-α blockade for the treatment of acute GVHD
Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., de Lima, M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4241 · Cited by 261
Alousi, A. M., Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., et al. (2009) · Blood · doi:10.1182/blood-2009-03-212290 · Cited by 222
Self-citationLee, S. J., Zahrieh, D., Agura, E., MacMillan, M. L., Maziarz, R. T., McCarthy, P. L., Ho, V. T., Cutler, C., Alyea, E. P., Antin, J. H., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0854 · Cited by 203
Self-citationThe best endpoint for acute GVHD treatment trials
MacMillan, M. L., DeFor, T. E., & Weisdorf, D. J. (2010) · Blood · doi:10.1182/blood-2009-12-258442 · Cited by 159
Ho, V. T., Zahrieh, D., Hochberg, E. P., Micale, E., Levin, J., Reynolds, C. G., Steckel, S., Cutler, C. S., Fisher, D. C., Lee, S. J., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0028 · Cited by 142
Self-citation
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Challenges and Controversies in Human Mesenchymal Stem Cell Therapy
Lukomska, B., Stanaszek, L., Zuba-Surma, E., Legosz, P., Sarzynska, S., & Drela, K. (2019) · Stem Cells International · doi:10.1155/2019/9628536 · Cited by 550
ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death
Vander Lugt, M. T., Braun, T. M., Hanash, S., Ritz, J., Ho, V. T., Antin, J. H., Zhang, Q., Wong, C.-H., Wang, H., Chin, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213299 · Cited by 405
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
Levine, J. E., Braun, T. M., Harris, A. C., Holler, E., Taylor, A., Miller, H., Magenau, J., Weisdorf, D. J., Ho, V. T., Bolaños-Meade, J., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(14)00035-0 · Cited by 309
Acute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 268
Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
Xu, X.-J., & Tang, Y.-M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.004 · Cited by 156
Metadata
- Authors
- Martin, P. J., Rizzo, J. D., Wingard, J. R., Ballen, K., Curtin, P. T., Cutler, C., Litzow, M. R., Nieto, Y., Savani, B. N., Schriber, J. R., Shaughnessy, P. J., Wall, D. A., & Carpenter, P. A.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 18
- Issue
- 8
- Pages
- 1150-1163
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2143258371
- Cited by
- 641
- References
- 17
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
